Live Breaking News & Updates on Moderna stock

Stay informed with the latest breaking news from Moderna stock on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Moderna stock and stay connected to the pulse of your community

Moderna Stock (NASDAQ:MRNA) at $100: Looking Past COVID-19 Vaccines for Profits

People depended on Moderna (NASDAQ:MRNA) in 2020 and 2021 for COVID-19 vaccines, but the pharma market landscape has changed dramatically since then. Now, Moderna has to demonstrate that it can evolve. Yet, the company’s latest quarterly report offers hope to frustrated shareholders. All in all, I am bullish on MRNA stock and envision a major turnaround story for 2024. Moderna is a well-known drug and vaccine manufacturer. The company doesn’t only develop COVID-19 vaccines, of course. In actuali

Michael-yee , Hartaj-singh , Profitable-quarter-takes-investors , Fiscal-year , Moves-past-its , Moderna-stock , Moderate-buy , Moderna , Oderna-stock ,

Moderna Stock Soars After Cancer Vaccine's Strong Test Results

he drug company’s latest vaccine, built from the same mRNA technology that created the Covid-19 vaccine, was found to significantly reduce risk of relapse or death from melanoma.

Arpa-garay , Stephen-hoge , Reuters , President-stephen-hoge , Chief-commercial-officer-arpa , Moderna-stock , Mrna , Moderna , Stéphane-bancel ,

Moderna Tops BioSpace's Best Places to Work Ranking for Third Consecutive Year

07.11.2023 - CAMBRIDGE, MA / ACCESSWIRE / November 7, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2024 Best Places to Work report for the third consecutive year.'We are proud to be named the best ...

Ihre-einstellungen , Lavina-talukdar , Kelly-cunningham , Communications-media , Moderna-inc , Moderna-university , Nasdaq , Best-places , Vice-president , Moderna-stock , Kurserwartungen-des-analysten , Sie-kursziel

Moderna vaccine for influenza: Trial shows promise, but falls short

Moderna’s influenza shot is based on the same technology as that of the successful Covid-19 vaccine.

Argentina , Australia , Colombia , Philippines , Panama , Stephen-hoge , World-health-organization , Does-covid , Southern-hemisphere , Vaccine-for-influenza , Influenza-vaccine-india , Flu-vaccine

Why Moderna Stock Is Popping Over 20% Today

Moderna Stock is ripping higher today after a cancer treatment breakthrough. Is Moderna stock a buy now?

Moderna-stock ,

Why Moderna Stock Is Popping Over 20% Today

Moderna Stock is ripping higher today after a cancer treatment breakthrough. Is Moderna stock a buy now?

Moderna-stock ,

Brad Miller Joins Moderna as Chief Information Officer

07.12.2022 - Current Chief Digital Officer, Marcello Damiani, to retire in MarchCAMBRIDGE, MA / ACCESSWIRE / December 7, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the ...

Waterloo , Ontario , Canada , Lavina-talukdar , Chris-ridley , Ihre-einstellungen , Mastercard , University-of-nottingham , Cloud-technology , Nasdaq , Microsoft , University-of-waterloo

Buy Moderna Stock | Invest in Moderna Stock Today at 0% Commission!

Read this guide to find out how to invest in Moderna stock. Learn how to buy Moderna stock at 0% commission today!

Australia , United-states , United-kingdom , Cyprus , America , American , Gary-mcfarlane , Challenger-bank-offering , Ally-bank , Nasdaq , Buy-moderna-stock , Moderna-stock

Moderna soars 6% as it begins vaccine testing in babies and children

Moderna soars 6% as it begins vaccine testing in babies and children
Isabelle Lee
Joseph Prezioso / AFP via Getty Images
Shares of Moderna rose 6.5% on Tuesday after the drugmaker announced it will begin testing its COVID-19 vaccine on children ages six months to 11 years.
Currently, Moderna's vaccines are approved only for adults 18 years and older.
While children have largely been spared from the virus, they still can become infected.
Shares of Moderna rose 6.5% on Tuesday after the drugmaker announced it will begin testing its COVID-19 vaccine on children ages six months to 11 years.
Currently, Moderna and Johnson & Johnson's vaccines have been given emergency use authorization for adults 18 years and older, while the vaccine from Pfizer and BioNTech are approved for people 16 years and older.

United-states , Canada , Pfizer , Biomedical-advanced-research , National-institute-of-allergy , Johnson , Development-authority , National-institute , Infectious-diseases , Mi-exclusive , Moderna